Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chromatin-bound RNA in a DLBCL cell line, OCI-LY7

ABSTRACT: Chromatin-bound RNA in a DLBCL cell line, OCI-LY7

PROVIDER: PRJNA605725 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11051076.fastq.gz	Fastqsanger.gz
	SRR11051077.fastq.gz	Fastqsanger.gz
	SRR11051078.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

Chromatin-bound RNA in a DLBCL cell line, OCI-LY7

Project description:We sequenced Chromatin-bound RNA (also known as ChromRNA-seq) to measure the transcriptional activity at enhancers.

2020-08-01 | GSE145017 | GEO

Methylation status of OCI Ly3 SP vs. nonSP

Project description:Promotor methylation status of Side Population cells of DLBCL cell line OCI Ly3 was compared to non Side Population Cells of OCI Ly3

2013-12-07 | GSE53043 | GEO

Methylation status of OCI Ly3 SP vs. nonSP

Project description:Promotor methylation status of Side Population cells of DLBCL cell line OCI Ly3 was compared to non Side Population Cells of OCI Ly3 DLBCL Cell Line OCI Ly3 was cultured and stained using Hoechst33342. FACS analysis showed a distinct Side Population. Side Population Cells and non Side Population cells were sorted, gDNA was extracted and Methylation analysis was performed using Illumin 27k Bead Array.

2013-12-07 | E-GEOD-53043 | biostudies-arrayexpress

Chromatin occupancy assessment an AML cell line treated with vehicle control, BETi, MDM2i, or a drug combination (BRD4-bound profiles)

Project description:BRD4 chromatin occupancy changes in human OCI-AML3 cells treated with DMSO (vehicle control), the BET inhibitor CPI-203, the MDM2 inhibitor Nutlin-3a, or a combination of both drugs, were compared. Method: Genomic DNA from the OCI-AML3 cell line treated for 24 hrs with either DMSO, CPI-203, Nutlin-3a or a combination of both drugs was extracted, BRD4-bound chromatin was immunoprecipitated, then DNA was sequenced with an Illumina NextSeq 500 sequencer. Sequence reads passing the quality control filters were aligned using Bowtie2 and then analysed with SICER.

2020-11-04 | GSE132247 | GEO

Chromatin occupancy assessment an AML cell line treated with vehicle control, BETi, MDM2i, or a drug combination (p53-bound profiles)

Project description:p53 chromatin occupancy changes in human OCI-AML3 cells treated with DMSO (vehicle control), the BET inhibitor CPI-203, the MDM2 inhibitor Nutlin-3a, or a combination of both drugs, were compared. Method: Genomic DNA from the OCI-AML3 cell line treated for 24 hrs with either DMSO, CPI-203, Nutlin-3a or a combination of both drugs was extracted, p53-bound chromatin was immunoprecipitated, then DNA was sequenced with an Illumina NextSeq 500 sequencer. Sequence reads passing the quality control filters were aligned using Bowtie2 and then analysed with MACS.

2020-11-04 | GSE132246 | GEO

High-throughput expression profiling of OCI-Ly3 cell line upon treatment with a panel of 14 known drugs.

2014-09-25 | GSE51068 | GEO

Recruitment of FOXP1 to target genes in diffuse large B-cell lymphoma (DLBCL) cells

Project description:Identification of FOXP1 target genes in the OCI-Ly1 DLBCL cell line by ChIP-on-chip

2013-05-03 | GSE44243 | GEO

Recruitment of FOXP1 to target genes in diffuse large B-cell lymphoma (DLBCL) cells

Project description:Identification of FOXP1 target genes in the OCI-Ly1 DLBCL cell line by ChIP-on-chip Three replicates of the FOXP1 ChIP-on-chip were performed in the OCI-Ly1 cells

2013-05-03 | E-GEOD-44243 | biostudies-arrayexpress

High-throughput expression profiling of OCI-Ly3 cell line upon treatment with a panel of 14 known drugs.

Project description:Analysis of Diffuse Large B-Cell Lymphoma (DLBCL) OCI-LY3 cell line treated with 14 different known drugs at 2 different concentrations and profiled at 6, 12 and 24 hrs after treatment. We used this gene expression data to design a challenge where participants were required to develop methods to predict activity of compound pairs using gene expression profile following single compound treatment, drug response curve of each compound and baseline genetic profile of OCI-LY3 cell line. GeneChip HT HG-U219 array plates were used to analyze gene expression changes induced by treatment with 14 drug compounds in OCI-Ly3 cells at 6, 12 and 24h. 3 replicates were analyxed for each drug/time combination. Vehicle (DMSO)-treated control samples were used for comparison with each replicate. Altogether 282 samples were analyzed in this study.

2014-09-25 | E-GEOD-51068 | biostudies-arrayexpress

CDK9 inhibition with AZD4573 in DLBCL

Project description:We report the effects of CDK9 inhibition (AZD4573) on the epigenetic landscape in Diffuse Large B-cell Lymphoma (DLBCL). This study utilized the Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) to assess genome-wide chromatin accessibility in two DLBCL cell lines, OCI-LY3 and VAL, treated with AZD4573 (30 nM) at 0, 3, and 8 hours. We found that CDK9 inhibition led to gain and loss of accessible chromatin genome-wide, with enrichment of CTCF/BORIS motifs in decreased accesibility regions.

2022-03-21 | GSE198851 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data